Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
about
Amphetamine, past and present--a pharmacological and clinical perspectiveA randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHDLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsUpdate on optimal use of lisdexamfetamine in the treatment of ADHD.A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating DisorderA systematic review of the safety of lisdexamfetamine dimesylate.Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsEfficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.Spontaneous coronary artery dissection in a 22-year-old man on lisdexamfetamineTreating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trialAttention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.Sustained treatment effect in attention-deficit/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studiesAnalysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate.Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorderThe use of lisdexamfetamine dimesylate for the treatment of ADHD.Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.The safety of extended-release drug formulations for the treatment of ADHD.Lisdexamfetamine: A Review in ADHD in Adults.Adult ADHD: A new disease?A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donorsParticipant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.Expert Opinion and Recommendations for the Management of Attention-Deficit/Hyperactivity Disorder in Correctional Facilities.Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder.Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial.A Long-Term, Open-Label, Safety Study of Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD.Six-year outcome in subjects diagnosed with attention-deficit/hyperactivity disorder as adults.A clinician's guide to ADHD treatment options.
P2860
Q22241826-BDD29FCB-A33F-43C9-A1E0-3B8690A8D97CQ24632726-712E8F0C-DE53-4BE1-97D5-C616CDC000D4Q26750486-66380DCE-D158-4D11-8209-78EC4A774DE8Q28246506-F52D58A4-5537-4D6B-8034-FB89943D63C2Q30418053-29E0D3FF-F3CC-4C72-9B84-1A796913E7B4Q33590913-6BF3374F-A6E5-46D7-8D3D-381C20483F61Q33755396-9CD06491-6998-4487-AB6D-054E50B16CEEQ34032634-8D897EB7-CDC0-4D7B-A248-46E1C4E23F63Q34220004-730CF629-6A39-4C26-80B2-287401D0F1C2Q34518522-7302558E-B5E8-4FB7-A6A4-3311938D1F35Q34565497-71303033-8C5A-46E3-BB3A-9E572086D1DEQ35627332-037C38CD-410B-4C6B-9F9C-EF8496E264A0Q35685121-25CEC20E-E20C-4965-B834-D31C2C0777E0Q35712166-31FCD00E-9EBE-4A29-A0D2-44D885150AAFQ35833310-B6E29ECF-221A-4F2E-BE81-B01951C3A58CQ35875805-372F3CC6-86E7-4C22-90DC-0671B8AF0892Q36100165-7D6B00E6-9134-4D2E-82DA-659155E5C018Q36740926-9701A2E9-DB8D-403B-ADED-5C7B63FCA27CQ37391143-3A79D363-27C4-4DF6-8F0D-BC36ADCE88F6Q37705738-06284323-D3BD-4F13-89D8-C50B868CC92EQ37975550-0BA96C67-16AD-45D0-85E9-C6DFA1AB2C86Q38187892-0E457B94-8195-4C5F-8464-F708B02902CDQ38221823-0D014FEB-4C2C-495F-B8B7-130F75CA5CFAQ38374695-F55F5DF5-1751-4B56-8399-EA29774157A8Q38732635-92B51E15-A996-4F9A-867A-048D2C48B557Q38799006-8974575B-643F-4DB8-BCE5-6854075FD8A8Q38799949-FAF22E7D-992D-4748-9217-B63FDAF3157BQ39017592-3DF3976D-4F5D-43D4-934B-1566853FAF36Q39478842-325D24D4-5E31-4C8C-8E3B-D6DE0D2E9A62Q39749601-B491681F-4A19-4A01-89CF-CBD4CF96B1D4Q40207289-EF3DA954-93F3-44FF-87EA-F2EA9174A9BAQ41522057-37C7536C-9D67-4D95-BDDC-B37479D67BC7Q42595344-88C7D153-CA80-4193-91DA-F2585C20F086Q46535632-013AAED4-4DF7-4693-A80E-64F5F90A9270Q47550500-21A9AB38-E97E-4F84-9167-4BA23DF6A158Q47586487-B21999E5-5DD7-47BB-B262-2E8C2B5A5C4BQ47741544-1141AB27-DD20-41C8-99DE-94DB33AF144DQ47741604-715EEB9B-4666-4BF3-8551-6A9F1A880505Q48295452-6DCD721D-2078-46C0-9EA1-9AAFC27EC468Q53132267-35083928-C719-43B9-81DE-BF98AB1FB99B
P2860
Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Long-term safety and effective ...... ficit/ hyperactivity disorder.
@en
Long-term safety and effective ...... ficit/ hyperactivity disorder.
@nl
type
label
Long-term safety and effective ...... ficit/ hyperactivity disorder.
@en
Long-term safety and effective ...... ficit/ hyperactivity disorder.
@nl
prefLabel
Long-term safety and effective ...... ficit/ hyperactivity disorder.
@en
Long-term safety and effective ...... ficit/ hyperactivity disorder.
@nl
P2093
P2860
P1433
P1476
Long-term safety and effective ...... eficit/ hyperactivity disorder
@en
P2093
304 Study Group
Greg Mattingly
Joel Young
Joseph Gao
Liza Squires
Richard Weisler
P2860
P304
P356
10.1017/S1092852900024056
P50
P577
2009-10-01T00:00:00Z